noon fri. huge buying/accumulation started,i am betting cdc approved and lawyers are writing news to distribute,meanwhile insiders at cdc loading,if i worked at cdc my nieces friends uncle's brothers nephews friends would be loading for me
Agree, 3 million volume the other day, mostly buys .
CEMI could breakout soon,thru200ma on 60 min,keep on watch ez$
completion of $3.2M contract awarded(sept.4) from cdc will come,no 20min test with conformation exists >Syphilis infections continue to be a significant health problem and are particularly threatening in high-risk groups and in people who are pregnant, where congenital syphilis can severely affect pregnancy outcome and infant morbidity. According to the CDC, the rate of primary and secondary syphilis?(the most infectious stages of the disease) has increased almost every year since the historic low in 2001–2002,?increasing 25.4% during 2020–2021, according to preliminary data. The timely identification and treatment of syphilis can decrease the transmission to others and result in better patient outcomes.
Serologic tests are currently available in clinical laboratories for the detection of active syphilis, which require shipping samples to perform tests of moderate or high complexity. There is no rapid point-of-care test currently available to accomplish both screening and confirmation of active syphilis. The development of such a test should allow for rapid diagnosis of an active infection and timely patient treatment, thus reducing the overall burden of syphilis in the U.S.
6 whale slaps@$30k-$60K last 2 days,shouldnt be long now
Agree, all we need some volume, I don’t mind the wait, hopefully one big paycheck
buy signals>stoch,momo,adx,crossing 6 month trendlines,bid keeps refilling as frontloading going on,should be 1 or 2 quick dips to trigger stop losses and nab cheap as shares are running out,watch for demand to trigger the run,low float so could run fast,low risk high reward from here
Signaturefd LLC raised its stake in shares of Chembio Diagnostics by 98.0% during the third quarter. Signaturefd LLC now owns 69,300 shares of the company’s stock valued at $25,000 after acquiring an additional 34,300 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Chembio Diagnostics by 383.4% during the third quarter. Renaissance Technologies LLC now owns 113,600 shares of the company’s stock valued at $41,000 after acquiring an additional 90,100 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Chembio Diagnostics by 41.4% during the third quarter. Vanguard Group Inc. now owns 1,562,014 shares of the company’s stock valued at $564,000 after acquiring an additional 457,450 shares during the last quarter.
AstraZeneca buyout like the 1.8B other one today would be nice
2M shares short,with china opening gates,covid tests needed,something is coming and insiders buying,news coming soon imo,year end and lastQ expected soon,could be good numbers,60 M revenue
It’s getting close to that time, squeeeeeeeeeeze
shares available to short just dropped 600%,running out,only 40k left
Could be the next $JSPR with the right news, IMO .
Loading and holding
“55,200,000 Shares of Common Stock
Pre-Funded Warrants to Purchase Shares of Common Stock
and Warrants to Purchase up to 69,000,000 Shares of Common Stock
We are offering 55,200,000 shares of common stock, par value $0.01 per share, together with warrants to purchase 69,000,000 shares of common stock. The common stock and warrants will be sold in a fixed combination, with each share of common stock accompanied by one and one-quarter (1.25) warrants to purchase one (1) share of common stock per whole warrant. The shares of common stock and warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. The assumed public offering price for each share of common stock and the accompanying warrants is $0.36, which was the last reported sale price of our common stock on The Nasdaq Capital Market on September 26, 2022.
The warrants will be exercisable only after we receive approval from our stockholders for both (i) an increase in the number of shares of common stock we are authorized to issue and/or a reverse stock split of our outstanding shares of common stock, each in an amount to be determined by the board of directors and each sufficient for the exercise in full of all of the warrants (an increase in authorized shares or a reverse stock split, each a “Capital Event”) and (ii) the potential issuance of shares of common stock upon exercise of the warrants in accordance with Nasdaq Marketplace Rule 5635(d) (the “Nasdaq Listing Rule”) ((i) and (ii), collectively, the “Stockholder Approvals” and the first date on which both Stockholder Approvals are obtained, the “Stockholder Approvals Date”). If our stockholders do not approve both a Capital Event and the potential issuance of shares of our common stock upon exercise of the warrants for purposes of the Nasdaq Listing Rule, the warrants will not become exercisable. Each warrant has an exercise price of $ per whole share, and will be exercisable on the Stockholder Approvals Date for a term of five years from the Stockholder Approvals Date.
We are also offering pre-funded warrants to purchase up to 55,200,000 shares of common stock to those purchasers whose purchase of shares of common stock in this offering would result in the purchaser beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock following the offering in lieu of the shares of common stock that would result in ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%). Each pre-funded warrant will be exercisable for one share of common stock at an exercise price of $0.01 per share. Each pre-funded warrant is being issued together with the same warrants described above that are being issued with each share of common stock. The assumed public offering price for each such pre-funded warrant and accompanying warrants is $0.35, which is equal to the assumed public offering price for a share of common stock and accompanying warrants less the $0.01 per share exercise price of each such pre-funded warrant. Each pre-funded warrant will be exercisable immediately upon issuance, subject to certain limitations based on the holder’s beneficial ownership of our common stock, and may be exercised at any time until the pre-funded warrant is exercised in full. The pre-funded warrants and warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. For each pre-funded warrant and accompanying warrants we sell, the number of shares of common stock and the accompanying warrants we are offering will be decreased on a one-for-one basis.
We are also registering the shares of common stock issuable upon exercise of the pre-funded warrants and the warrants in this prospectus.
Our common stock is listed on The Nasdaq Capital Market under the symbol “CEMI.” On September 26, 2022, the last reported sale price of our common stock on The Nasdaq Capital Market was $0.36 per share. The recent market price used throughout this prospectus may not be indicative of the final offering price. The final offering price will be determined through negotiation between us and the underwriter based upon a number of factors, including our history and our prospects, the industry in which we operate, our past and present operating results and the general condition of the securities markets at the time of this offering. There is no established public trading market for the pre-funded warrants or the warrants, and we do not expect a market to develop. We do not intend to apply for listing of the pre-funded warrants or the warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the pre-funded warrants and the warrants will be extremely limited.”
GM buddy, another 1 for the winners circle ty choo-choo!!!
Chembio Diagnostics Evaluates Monkeypox Rapid Point-of-Care Test Development
August 16 2022 - 08:00AM
Share On Facebook
Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it is evaluating the potential to develop a monkeypox rapid point-of-care (POC) test. Chembio is exploring the technical requirements for test development leveraging its multiple technology platforms, DPP, SURE CHECK, and STAT PAK, along with funding partners and the broader market opportunity.
“We are in dialogue with leading health organizations at the federal and state level to evaluate the need for a rapid test to detect and diagnose monkeypox. We are assessing the market needs, timing, regulatory pathway and investment required to develop a test,” said Richard Eberly, Chembio’s President and Chief Executive Officer. “Current tests available for monkeypox are PCR based, and given our history of developing rapid POC tests for infectious disease outbreaks, we believe we may be positioned to leverage our technology to provide a differentiated rapid solution. Based on our findings we will determine if this is a viable future opportunity for Chembio.”
Monkeypox is a rare disease caused by infection with the monkeypox virus. Monkeypox virus is part of the same family of viruses as variola virus, the virus that causes smallpox with symptoms similar to smallpox symptoms, but milder, and rarely fatal. Monkeypox can spread from person to person through direct contact with the infectious rash, scabs, or body fluids. It also can be spread by respiratory secretions during prolonged, face-to-face contact, or during intimate physical contact. There are now over 11,000 total confirmed monkeypox cases in the United States.
Chembio has a track record of delivering testing solutions for three recent infectious disease outbreaks with the expedited development rapid point-of-care tests. This includes the rapid development of a Zika product for the U.S. market, when the Zika outbreak was impacting the United States in 2017. The company also developed a DPP Ebola test to help with the outbreak with Ebola in 2018. This was followed by the development of COVID tests when the pandemic hit the U.S. in 2020. Additionally, Chembio has developed rapid point-of-care DPP diagnostic tests for HIV 1/2 and Syphilis with the introduction of STAT PAK and SURE CHECK.
Currently, the FDA has cleared one test to detect monkeypox, offered through the U.S. Centers for Disease Control and Prevention (CDC) as a lab developed test (LDT). The test utilizes a swab sample from a monkeypox lesion, creating the need for earlier detection to limit the spread of the disease and expedite treatment.
About the DPP Rapid Test Platform
Chembio’s proprietary DPP technology platform provides high-quality, rapid diagnostic results in 15 to 20 minutes using a small drop of blood from the fingertip or alternative samples. Through advanced multiplexing, the DPP platform can detect up to eight, distinct test results from a single patient sample, delivering greater clinical value than other rapid tests. For certain applications, Chembio’s easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzer then reports accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on-site. Objective results produced by the DPP Micro Reader reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.
Chembio’s portfolio of DPP-based point-of-care tests with FDA regulatory approvals include the DPP HIV-Syphilis System (PMA approved), DPP HIV 1/2 Assay (PMA approved and CLIA waived), DPP Zika IgM System (510(k)), and DPP Ebola Antigen System (EUA). Additionally, DPP-based tests have received regulatory approvals from the World Health Organization, CE-Mark, ANVISA, and other global organizations, where they aid in the detection and diagnosis of several other critical diseases and conditions.
All DPP tests are developed and manufactured in the United States and are the subject of a range of domestic and global patents and patents pending.
About Chembio Diagnostics
Chembio is a leading diagnostics company focused on developing and commercializing point-of-care tests used to detect and diagnose infectious diseases, including sexually transmitted disease, insect vector and tropical disease, COVID-19 and other viral and bacterial infections, enabling expedited treatment. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
Certain statements contained in the first and second paragraphs above are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the opportunity, timing and operational and financial success of Chembio’s d
stock is increasing close to 48% ahead of its earnings report tomorrow.